BR112016006830A2 - composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas - Google Patents

composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas

Info

Publication number
BR112016006830A2
BR112016006830A2 BR112016006830A BR112016006830A BR112016006830A2 BR 112016006830 A2 BR112016006830 A2 BR 112016006830A2 BR 112016006830 A BR112016006830 A BR 112016006830A BR 112016006830 A BR112016006830 A BR 112016006830A BR 112016006830 A2 BR112016006830 A2 BR 112016006830A2
Authority
BR
Brazil
Prior art keywords
topical
composition
spray composition
topical spray
halobetasol
Prior art date
Application number
BR112016006830A
Other languages
English (en)
Inventor
Rana Anil
Trehan Anupam
Vinod Arora Kumar
Madan Sumit
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR112016006830A2 publication Critical patent/BR112016006830A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

a presente invenção refere-se a composições de spray tópico de halobetasol, compreendendo um emoliente, um solvente não aquoso, e um propelente. ela refere-se também a um processo para a preparação das composições de spray tópico. ela refere-se ainda a um método de tratamento para uma condição da pele tópica através da administração das referidas composições de spray tópico.
BR112016006830A 2013-09-25 2014-09-22 composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas BR112016006830A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2839DE2013 2013-09-25
PCT/IB2014/064745 WO2015044857A1 (en) 2013-09-25 2014-09-22 Topical spray composition of halobetasol

Publications (1)

Publication Number Publication Date
BR112016006830A2 true BR112016006830A2 (pt) 2017-08-01

Family

ID=51626113

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016006830A BR112016006830A2 (pt) 2013-09-25 2014-09-22 composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas
BR132017012408-7A BR132017012408E2 (pt) 2013-09-25 2017-06-09 Composto, processo para a preparação de um composto, composições farmacêuticas tópicas estáveis de halobetasol

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR132017012408-7A BR132017012408E2 (pt) 2013-09-25 2017-06-09 Composto, processo para a preparação de um composto, composições farmacêuticas tópicas estáveis de halobetasol

Country Status (8)

Country Link
US (1) US20160256474A1 (pt)
EP (1) EP3049063A1 (pt)
AU (1) AU2014326199A1 (pt)
BR (2) BR112016006830A2 (pt)
CA (1) CA2925676A1 (pt)
MX (1) MX2016003951A (pt)
RU (1) RU2016115481A (pt)
WO (1) WO2015044857A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6997624B2 (ja) 2015-06-18 2022-01-17 ボシュ ヘルス ユーエス，エルエルシー． 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物
US10857159B2 (en) * 2015-12-15 2020-12-08 Mayne Pharma Llc Halobetasol foam composition and method of use thereof
SG11201805111VA (en) 2015-12-15 2018-07-30 Therapeutics Inc Corticosteroid containing foam compositions and method of manufacture thereof
US20170340649A1 (en) 2016-05-30 2017-11-30 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
WO2018020386A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Topical spray system of halobetasol
ES2905445T3 (es) 2016-10-21 2022-04-08 Crescita Therapeutics Inc Composiciones farmacéuticas
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
WO2019224035A1 (en) 2018-05-24 2019-11-28 Almirall, S.A. Topical pharmaceutical compositions comprising a corticosteroid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6579512B2 (en) 2001-06-15 2003-06-17 Crutchfield, Iii Charles E. Topical steroid spray
US20080107758A1 (en) 2001-06-15 2008-05-08 Cuticeuticals, Inc. Topical steroid spray with botanic seed oils
WO2007039825A2 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
WO2006130510A2 (en) * 2005-05-27 2006-12-07 Taro Pharmaceuticals U.S.A., Inc. Stable liquid desoximethasone compositions with reduced oxidized impurity
WO2009007785A2 (en) 2006-11-14 2009-01-15 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20090136430A1 (en) * 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis

Also Published As

Publication number Publication date
US20160256474A1 (en) 2016-09-08
RU2016115481A3 (pt) 2018-06-29
EP3049063A1 (en) 2016-08-03
RU2016115481A (ru) 2017-10-30
CA2925676A1 (en) 2015-04-02
MX2016003951A (es) 2016-07-06
WO2015044857A1 (en) 2015-04-02
AU2014326199A1 (en) 2016-04-28
BR132017012408E2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
BR112016006830A2 (pt) composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas
CO2018001375A2 (es) Composiciones de retinoides tópicos
MX374480B (es) Formulaciones de espiro-isoxazolina de accion prolongada.
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CO2017002472A2 (es) Formulación de acetato de abiraterona
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
MX376183B (es) Composiciones para el tratamiento de rosacea.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
WO2014152385A3 (en) Cranial delivery of pharmaceuticals
CY1121841T1 (el) Τοπικη αντιμυκητιασικη συνθεση για τη θεραπεια της ονυχομυκητιασης
MX390480B (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
GT201400146A (es) Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides
BR112016002643A8 (pt) composições para tratamento de pele e método para produção de uma composição para tratamento de pele
BR112016006826A2 (pt) composição de spray tópico de halobetasol sem propelente, sistema de distribuição para a administração da composição de spray tópico, processo para a preparação da composição de spray tópico e método para o tratamento de condições de pele tópica
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
BR112015020182A2 (pt) uso cosmético de queuina ou de um precursor ou um derivado dessa como ingrediente ativo, uso de queuina ou um precursor ou um derivado dessa como ingrediente ativo, composição cosmética e processo de tratamento cosmético para prevenir e/ou tratar sinais de envelhecimento da pele e/ou anexos cutâneos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.